blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2769727

EP2769727 - DEOXYNUCLEOSIDE/NUCLEOSIDE COMBINATION FOR USE IN THE TREATMENT OF TUMORS [Right-click to bookmark this link]
Former [2014/35]USE FOR DEOXYNUCLEOSIDE/NUCLEOSIDE COMBINATION IN PREPARATION OF TUMOR MEDICAMENT
[2016/08]
StatusNo opposition filed within time limit
Status updated on  24.03.2017
Database last updated on 06.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Zhang, Shizhuang
No. 2428 Yuhe Road
Kuiwen District
Weifang, Shandong 261031 / CN
[2014/35]
Inventor(s)01 / ZHANG, Shizhuang
No.2428 Yuhe Road
Weifang Shandong 261031 / CN
02 / CHENG, Xin
No.7166 Baotong West Street
Weifang Shandong 261053 / CN
03 / GAO, Zhiqin
No.7166 Baotong West Street
Weifang Shandong 261053 / CN
04 / HAN, Ming
No.7166 Baotong West Street
Weifang Shandong 261053 / CN
 [2016/18]
Former [2014/35]01 / CHENG, Xin
No.7166 Baotong West Street
Weifang Shandong 261053 / CN
02 / GAO, Zhiqin
No.7166 Baotong West Street
Weifang Shandong 261053 / CN
03 / HAN, Ming
No.7166 Baotong West Street
Weifang Shandong 261053 / CN
Representative(s)Sun, Yiming
HUASUN Patent- und Rechtsanwälte
Friedrichstraße 33
80801 München / DE
[2014/35]
Application number, filing date12842329.016.10.2012
[2016/20]
WO2012CN01392
Priority number, dateCN20111031430917.10.2011         Original published format: CN201110314309
[2014/35]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013056510
Date:25.04.2013
Language:ZH
[2013/17]
Type: A1 Application with search report 
No.:EP2769727
Date:27.08.2014
Language:EN
[2014/35]
Type: B1 Patent specification 
No.:EP2769727
Date:18.05.2016
Language:EN
[2016/20]
Search report(s)International search report - published on:CN25.04.2013
(Supplementary) European search report - dispatched on:EP19.08.2014
ClassificationIPC:A61K31/708, A61K31/7076, A61K31/7072, A61K31/7068, A61P35/00, A61P35/02
[2014/35]
CPC:
A61K31/708 (EP,US); A61K31/7068 (EP,US); A61K31/7072 (EP,US);
A61K31/7076 (EP,US); A61P35/00 (EP); A61P35/02 (EP)
C-Set:
A61K31/7068, A61K2300/00 (EP,US);
A61K31/7072, A61K2300/00 (US,EP);
A61K31/7076, A61K2300/00 (US,EP);
A61K31/708, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/35]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:DESOXYNUKLEOSID-/NUKLEOSID-KOMBINATION ZUR VERWENDUNG BEI DER BEHANDLUNG VON TUMOREN[2016/08]
English:DEOXYNUCLEOSIDE/NUCLEOSIDE COMBINATION FOR USE IN THE TREATMENT OF TUMORS[2016/08]
French:COMBINAISON DÉSOXYNUCLÉOSIDE/NUCLÉOSIDE POUR UTILISATION DANS LE TRAITEMENT DE TUMEURS[2016/08]
Former [2014/35]VERWENDUNG ZUR DESOXYNUKLEOSID-/NUKLEOSID-KOMBINATION BEI DER HERSTELLUNG VON TUMORARZNEIMITTELN
Former [2014/35]USE FOR DEOXYNUCLEOSIDE/NUCLEOSIDE COMBINATION IN PREPARATION OF TUMOR MEDICAMENT
Former [2014/35]UTILISATION D'UNE COMBINAISON DÉSOXYNUCLÉOSIDE/NUCLÉOSIDE DANS LA PRÉPARATION D'UN MÉDICAMENT ANTITUMORAL
Entry into regional phase13.05.2014Translation filed 
13.05.2014National basic fee paid 
13.05.2014Search fee paid 
13.05.2014Designation fee(s) paid 
13.05.2014Examination fee paid 
Examination procedure13.05.2014Examination requested  [2014/35]
23.01.2015Amendment by applicant (claims and/or description)
30.04.2015Despatch of a communication from the examining division (Time limit: M04)
18.08.2015Reply to a communication from the examining division
27.10.2015Despatch of a communication from the examining division (Time limit: M04)
19.11.2015Reply to a communication from the examining division
19.02.2016Communication of intention to grant the patent
31.03.2016Fee for grant paid
31.03.2016Fee for publishing/printing paid
31.03.2016Receipt of the translation of the claim(s)
12.04.2016Observations by third parties
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.04.2015
Opposition(s)21.02.2017No opposition filed within time limit [2017/17]
Fees paidRenewal fee
16.09.2014Renewal fee patent year 03
29.10.2015Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL18.05.2016
AT18.05.2016
BG18.05.2016
CY18.05.2016
CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
IS18.05.2016
LT18.05.2016
LV18.05.2016
MC18.05.2016
MK18.05.2016
RS18.05.2016
SI18.05.2016
SK18.05.2016
SM18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
LU16.10.2016
MT31.10.2016
[2018/46]
Former [2018/38]AT18.05.2016
BG18.05.2016
CY18.05.2016
CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
IS18.05.2016
LT18.05.2016
LV18.05.2016
MC18.05.2016
MK18.05.2016
RS18.05.2016
SI18.05.2016
SK18.05.2016
SM18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
LU16.10.2016
MT31.10.2016
Former [2018/31]AT18.05.2016
CY18.05.2016
CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
IS18.05.2016
LT18.05.2016
LV18.05.2016
MC18.05.2016
MK18.05.2016
RS18.05.2016
SI18.05.2016
SK18.05.2016
SM18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
LU16.10.2016
MT31.10.2016
Former [2017/40]AT18.05.2016
CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
LT18.05.2016
LV18.05.2016
MC18.05.2016
RS18.05.2016
SI18.05.2016
SK18.05.2016
SM18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
LU16.10.2016
Former [2017/37]AT18.05.2016
CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
LT18.05.2016
LV18.05.2016
MC18.05.2016
RS18.05.2016
SI18.05.2016
SK18.05.2016
SM18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
Former [2017/11]AT18.05.2016
CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
LT18.05.2016
LV18.05.2016
RS18.05.2016
SK18.05.2016
SM18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
Former [2017/10]CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
LT18.05.2016
LV18.05.2016
RS18.05.2016
SK18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
Former [2017/09]CZ18.05.2016
EE18.05.2016
FI18.05.2016
HR18.05.2016
LT18.05.2016
LV18.05.2016
RS18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
Former [2016/51]FI18.05.2016
HR18.05.2016
LT18.05.2016
LV18.05.2016
RS18.05.2016
NO18.08.2016
GR19.08.2016
PT19.09.2016
Former [2016/50]FI18.05.2016
HR18.05.2016
LT18.05.2016
LV18.05.2016
RS18.05.2016
NO18.08.2016
Former [2016/49]FI18.05.2016
LT18.05.2016
NO18.08.2016
Former [2016/46]LT18.05.2016
NO18.08.2016
Documents cited:Search[X]GB1270049  (SYLVEN BENGT [SE]) [X] 1-5,7,8 * claim 2 * * column 1, lines 9-14 * * examples 4-6 *;
 [X]US2001044421  (VON BORSTEL REID W [US], et al) [X] 1-5,7,8 * claims 150-153 * * examples 2, 7 *;
 [X]CN102172359  (SHIZHUANG ZHANG) [X] 1-5,7,8 * claims 1-10 *;
 [A]  - KIM K T ET AL, "The effect of pyrimidine nucleosides on adenosine-induced apoptosis in HL-60 cells", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 1998 DE, (1998), vol. 124, no. 9, ISSN 0171-5216, pages 471 - 477, XP002728120 [A] 1-8 * abstract * * figures 2, 4 *

DOI:   http://dx.doi.org/10.1007/s004320050201
 [A]  - LOWE J K ET AL, "Inhibition of growth rate and deoxynucleoside triphosphate concentrations in cultured leukemia L1210 cells", MOLECULAR PHARMACOLOGY, (1976), vol. 12, no. 1, ISSN 0026-895X, pages 177 - 184, XP009179465 [A] 1-8 * abstract * * page 179, column 1, paragraph 2 - page 180, column 1, paragraph 1 * * page 182, column 2, paragraph 2 *
 [A]  - COHEN J D ET AL, "Deoxyribonucleoside triphosphate pools and thymidine chemosensitization in human T-cell leukemia", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 17, no. 2, ISSN 0145-2126, (199302), pages 167 - 174, (19930201), XP026353256 [A] 1-8 * abstract *
 [A]  - FRIED J ET AL, "Cytotoxic and cytokinetic effects of thymidine, 5-fluorouracil, and deoxycytidine on HeLa cells in culture", CANCER RESEARCH, (1981), vol. 41, no. 7, ISSN 0008-5472, pages 2627 - 2632, XP002728121 [A] 1-8 * abstract * * page 2629, column 2, paragraph 3 *
 [A]  - ROSS D D ET AL, "Effects of deoxynucleosides on cultured human leukemia cell growth and deoxynucleotide pools.", CANCER RESEARCH NOV 1981, (198111), vol. 41, no. 11 Pt 1, ISSN 0008-5472, pages 4493 - 4498, XP002728122 [A] 1-8 * abstract *

DOI:   http://dx.doi.org/http://cancerres.aacrjournals.org/content/41/11_Part_1/4493
 [A]  - ZHEN Y S ET AL, "Effects of acivicin and dipyridamole on hepatoma 3924A cells.", CANCER RESEARCH APR 1983, (198304), vol. 43, no. 4, ISSN 0008-5472, pages 1616 - 1619, XP055132458 [A] 1-8 * abstract *
International search[Y]WO9902143  (CAN FITE TECHNOLOGIES LTD [IL], et al);
 [A]US2002198183  (ROBINS H IAN [US]);
 [X]CN102172359  (SHIZHUANG ZHANG);
 [XP]CN102499937  (SHIZHUANG ZHANG)
other   - CHENG XIN; QU LINTAO; ZHANG SHIZHUANG; WANG BIN; PAN XIAOJIE, "Construction of mice colon cancer transplantation tumor model and multiple mice MRI studies", Chinese Journal of Medical Imaging Technology, (20080000), vol. 24, no. 9, pages 1345 - 1347
    - CHENG XIN; DAI SHENG; ZHANG SHIZHUANG; WANG BIN; YANG KUIHUA, "MRI evaluation of the curative effect of gecko's active ingredients on rabbit VX2 liver transplantation tumor", Chinese Journal of Medical Imaging Technology, (20100000), vol. 26, no. 5, pages 812 - 814
    - CHENG XIN; ZHANG SHIZHUANG; WANG BIN; DONG PENG, "Expression and clinical significance of CD44v6, MMP_9 and VEGF in gastric cancer tissue", Proceedings of Weifang Medical College, (20080000), vol. 30, no. 4, pages 319 - 321
    - CHENG XIN; HAN MING; ZHANG SHIZHUANG; WANG BIN; QU LINTAO, "Expression and clinical significance of CD44v6 and MMP-9 in gastric cancer", Progress in Modern Biomedicine, (20080000), vol. 8, no. 11, pages 2051 - 2053
    - DAI SHENG; CHENG XIN; WANG BIN; ZHANG YUEMEI; DONG PENG; ZHANG SHIZHUANG, "The relationship of spiral CT signs of gastric carcinoma with CD44v6 and MMP-9", Proceedings of Weifang Medical College, (20080000), vol. 30, no. 5, pages 422 - 424
    - CHENG XIN; QU LINTAO; ZHANG SHIZHUANG; WANG BIN; PAN XIAOJIE, "Experimental studies of multiple mice MRI to observe the curative effect of mice colon cancer transplanted tumor endothelial inhibition", Journal of Clinical Radiology, (20080000), vol. 27, no. 10, pages 1419 - 1422
    - CHENG XIN; QU LINTAO; ZHANG SHIZHUANG; WANG BIN; MENG FANLIAN, "Experimental studies of multiple mice MRI to evaluate the curative effect of mice colon cancer endothelial inhibition", Journal of Practical Radiology, (20080000), vol. 24, no. 8, pages 1125 - 1128
    - HAN MING; CHENG XIN; ZHANG SHIZHUANG; WANG BIN; QU LINTAO, "Application value of ADC value in the therapeutic evaluation of endothelial inhibition for mice colon cancer", Chinese Journal of Medical Imaging Technology, (20090000), vol. 25, no. 6, pages 963 - 965
    - HAN MING; CHENG XIN; ZHANG SHIZHUANG, "Studies of diffusion weighted imaging endothelial inhibition for the efficacy of mice colon cancer and its correlation with tumor cell density", Journal of Practical Radiology, (20090000), vol. 25, no. 8, pages 1191 - 1194
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.